series-a
Stage
1
Investors
About
Zag Bio develops thymus-targeted bifunctional antibody therapies that induce T cell central tolerance to treat autoimmune diseases by retraining the immune system to tolerate the body's own tissues.
Explore Zag Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.